Quantitative Risk/Benefit Assessment: Where Are We?

[1]  Jonathan D. Norton,et al.  A Longitudinal Model and Graphic for Beneft-risk Analysis, With Case Study , 2011 .

[2]  B S Levitan,et al.  Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit–Risk Balance of Medicines , 2011, Clinical pharmacology and therapeutics.

[3]  B S Levitan,et al.  Application of the BRAT Framework to Case Studies: Observations and Insights , 2011, Clinical pharmacology and therapeutics.

[4]  P. Honig Comparative Effectiveness: The Fourth Hurdle in Drug Development and a Role for Clinical Pharmacology , 2011, Clinical pharmacology and therapeutics.

[5]  J. Kramer,et al.  Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values. , 2009, The New England journal of medicine.

[6]  J. Werth,et al.  The Use of a Clinical Utility Index to Compare Insomnia Compounds: A Quantitative Basis for Benefit–Risk Assessment , 2009, Clinical pharmacology and therapeutics.

[7]  R. Tamura,et al.  Global benefit–risk assessment in designing clinical trials and some statistical considerations of the method , 2008, Pharmaceutical statistics.

[8]  Christy Chuang-Stein,et al.  Measures for Conducting Comparative Benefit: Risk Assessment , 2008 .

[9]  Robert T. O'Neill,et al.  A Perspective on Characterizing Benefits and Risks Derived from Clinical Trials: Can We Do More? , 2008 .

[10]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[11]  R. Temple Quantitative Decision Analysis: A Work in Progress , 2007, Clinical pharmacology and therapeutics.

[12]  M Pirmohamed,et al.  Current Assessment of Risk–Benefit by Regulators: Is It Time to Introduce Decision Analyses? , 2007, Clinical pharmacology and therapeutics.

[13]  Sam Salek,et al.  Retracted:A quantitative approach to benefit‐risk assessment of medicines — part 2: the practical application of a new model , 2007, Pharmacoepidemiology and drug safety.

[14]  Sam Salek,et al.  A quantitative approach to benefit‐risk assessment of medicines – part 1: the development of a new model using multi‐criteria decision analysis , 2007, Pharmacoepidemiology and drug safety.

[15]  H. Mouridsen,et al.  Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  R. Entsuah,et al.  Global Benefit-risk Evaluation of Antidepressant Action: Comparison of Pooled Data for Venlafaxine, SSRIs, and Placebo , 2002, CNS Spectrums.

[17]  Richard Entsuah,et al.  Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. , 2002, Journal of psychiatric research.

[18]  C Chuang-Stein,et al.  A new proposal for benefit-less-risk analysis in clinical trials. , 1994, Controlled clinical trials.

[19]  C Chuang-Stein,et al.  Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. , 1991, Statistics in medicine.

[20]  R. Gelber,et al.  Quality adjusted survival analysis. , 1990, Statistics in medicine.

[21]  R. Gelber,et al.  A quality-of-life-oriented endpoint for comparing therapies. , 1989, Biometrics.